文献速递心力衰竭与心肌病瓣膜病与结构性心脏病

Aficamten 对心肺运动试验表现的影响:SEQUOIA-HCM 随机临床试验亚组分析

Aficamten and Cardiopulmonary Exercise Test Performance: A Substudy of the SEQUOIA-HCM Randomized Clinical Trial.
PubMed 文献 · JAMA Cardiol · 2024-01-01

该研究为 SEQUOIA-HCM 随机对照试验的预设分析,纳入 282 例有症状的梗阻性肥厚型心肌病患者,随机接受 aficamten(5-20 mg 每日)或安慰剂治疗 24 周。结果显示,aficamten 组整合运动表现 z 评分较基线改善(0.17),而安慰剂组恶化(-0.19),安慰剂校正后改善为 0.35(95%CI 0.25-0.46;P<.001),且多项运动指标显著改善。

要点

  • Aficamten 显著改善梗阻性 HCM 患者的整合运动表现(pVO2 与 VE/VCO2 斜率 z 评分)。
  • Aficamten 组 pVO2 大幅改善(≥3.0 mL/kg/min)比例高于大幅下降比例(32% vs 2%)。
  • 运动指标改善与症状负担及血流动力学改善显著相关(均 P<.05)。

核心结论

  • Aficamten 治疗可广泛改善梗阻性 HCM 患者的多项运动表现指标。

研究设计与样本

  • SEQUOIA-HCM 为双盲、安慰剂对照、随机临床试验的预设分析。
  • 从 14 个国家 101 个中心招募 282 例有症状梗阻性 HCM 且客观运动不耐受(pVO2≤90% 预测值)患者。
  • 按 1:1 随机接受 aficamten(5-20 mg 每日)或匹配安慰剂治疗 24 周。
  • 263 例(93.3%)有核心实验室验证的基线和第 24 周运动试验数据。

主要发现

  • Aficamten 组整合运动表现 z 评分从基线至第 24 周平均(SD)改善 0.17(0.51),安慰剂组恶化 -0.19(0.45)。
  • 安慰剂校正后整合运动表现改善为 0.35(95%CI 0.25-0.46;P<.001)。
  • Aficamten 组总做功量、循环功率、运动持续时间、心率储备、峰值心率、通气效率、通气功率和无氧阈均显著改善(均 P<.001)。
  • Aficamten 组 pVO2 大幅改善(≥3.0 mL/kg/min)比例为 32%,大幅下降比例为 2%;安慰剂组分别为 16% 和 11%。
  • pVO2 和 VE/VCO2 斜率两组成部分的改善均与症状负担及血流动力学改善显著相关(均 P<.05)。

临床怎么用

  • 对于有症状梗阻性 HCM 且运动不耐受患者,aficamten 可改善心肺运动试验多项指标。
  • 临床可关注 pVO2 和 VE/VCO2 斜率作为评估治疗反应的整合指标。

局限性

  • 原文未报告局限性内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Impaired exercise capacity is a cardinal manifestation of obstructive hypertrophic cardiomyopathy (HCM). The Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Obstructive HCM (SEQUOIA-HCM) is a pivotal study characterizing the treatment effect of aficamten, a next-in-class cardiac myosin inhibitor, on a comprehensive set of exercise performance and clinical measures. OBJECTIVE: To evaluate the effect of aficamten on exercise performance using cardiopulmonary exercise testing with a novel integrated measure of maximal and submaximal exercise performance and evaluate other exercise measures and clinical correlates. DESIGN, SETTING, AND PARTICIPANTS: This was a prespecified analysis from SEQUOIA-HCM, a double-blind, placebo-controlled, randomized clinical trial. Patients were recruited from 101 sites in 14 countries (North America, Europe, Israel, and China). Individuals with symptomatic obstructive HCM with objective exertional intolerance (peak oxygen uptake [pVO2] ≤90% predicted) were included in the analysis. Data were analyzed from January to March 2024. INTERVENTIONS: Randomized 1:1 to aficamten (5-20 mg daily) or matching placebo for 24 weeks. MAIN OUTCOMES AND MEASURES: The primary outcome was change from baseline to week 24 in integrated exercise performance, defined as the 2-component z score of pVO2 and ventilatory efficiency throughout exercise (minute ventilation [VE]/carbon dioxide output [VCO2] slope). Response rates for achieving clinically meaningful thresholds for change in pVO2 and correlations with clinical measures of treatment effect (health status, echocardiographic/cardiac biomarkers) were also assessed. RESULTS: Among 282 randomized patients (mean [SD] age, 59.1 [12.9] years; 115 female [40.8%], 167 male [59.2%]), 263 (93.3%) had core laboratory-validated exercise testing at baseline and week 24. Integrated composite exercise performance improved in the aficamten group (mean [SD] z score, 0.17 [0.51]) from baseline to week 24, whereas the placebo group deteriorated (mean [SD] z score, -0.19 [0.45]), yielding a placebo-corrected improvement of 0.35 (95% CI, 0.25-0.46; P <.001). Further, aficamten treatment demonstrated significant improvements in total workload, circulatory power, exercise duration, heart rate reserve, peak heart rate, ventilatory efficiency, ventilatory power, and anaerobic threshold (all P <.001). In the aficamten group, large improvements (≥3.0 mL/kg per minute) in pVO2 were more common than large reductions (32% and 2%, respectively) compared with placebo (16% and 11%, respectively). Improvements in both components of the primary outcome, pVO2 and VE/VCO2 slope throughout exercise, were significantly correlated with improvements in symptom burden and hemodynamics (all P <.05). CONCLUSIONS AND RELEVANCE: This prespecified analysis of the SEQUOIA-HCM randomized clinical trial found that aficamten treatment improved a broad range of exercise performance measures. These findings offer valuable insight into the therapeutic effects of aficamten. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05186818.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Lee MMY, Masri A, Nassif ME, et al. Aficamten and Cardiopulmonary Exercise Test Performance: A Substudy of the SEQUOIA-HCM Randomized Clinical Trial. JAMA Cardiol. 2024. PMID: 39230885. doi:10.1001/jamacardio.2024.2781

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。